Forma Therapeutics Holdings, Inc. Sustainability Profile
Forma Therapeutics Holdings, Inc., a leading biopharmaceutical company based in the United States, is dedicated to transforming the lives of patients with rare diseases and cancers. Founded in 2010, Forma has made significant strides in drug discovery and development, focusing on innovative therapies that target specific genetic mutations. With a strong emphasis on precision medicine, Forma Therapeutics is renowned for its unique approach to developing small molecule therapies, particularly in the areas of sickle cell disease and other haematological disorders. The company has achieved notable milestones, including advancing its lead product candidates through various stages of clinical trials, positioning itself as a key player in the biopharmaceutical industry. Through its commitment to scientific excellence and patient-centric solutions, Forma Therapeutics continues to enhance its market position, striving to deliver transformative treatments that address unmet medical needs.
DitchCarbon Score
How does Forma Therapeutics Holdings, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Forma Therapeutics Holdings, Inc.'s score of 56 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Forma Therapeutics Holdings, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Novo Nordisk A/S, and as such, it inherits emissions data and climate commitments from its parent organisation. While Forma Therapeutics has not disclosed its own emissions figures, it aligns with the sustainability initiatives and targets set by Novo Nordisk A/S. This includes commitments to the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, all of which are aimed at reducing carbon emissions and promoting renewable energy usage. As a subsidiary, Forma Therapeutics is expected to contribute to the overarching climate goals established by Novo Nordisk, which include significant reduction targets across various scopes of emissions. However, specific reduction targets or achievements for Forma Therapeutics itself have not been detailed. In summary, while Forma Therapeutics Holdings, Inc. does not provide its own emissions data or specific climate commitments, it is part of a corporate family that prioritises sustainability and has established frameworks for reducing carbon emissions through its parent company, Novo Nordisk A/S.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 86,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 75,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 00,000,000 | - | - | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Forma Therapeutics Holdings, Inc.'s Industry?
How Carbon Intensive is Forma Therapeutics Holdings, Inc.'s Location?
Forma Therapeutics Holdings, Inc.'s Scope 3 Categories Breakdown
Forma Therapeutics Holdings, Inc.'s Scope 3 emissions, which increased by 24% last year and increased significantly since 2020, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 56% of Scope 3 emissions.
Top Scope 3 Categories
Forma Therapeutics Holdings, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Forma Therapeutics Holdings, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
